



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

BDM-I Presentation at European Clinical Conference

Melbourne, 13 April 2016: Australian infectious disease therapy and vaccine development company BioDiem Ltd today announced the presentation by Western Sydney University (WSU) PhD candidate Michael Radzieta, at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Amsterdam this week.

Michael's presentation is entitled "Investigating the Mechanism of Action of the Novel Antimicrobial BDM-I" and is part of the session "Discovery and novel developments in antibacterial drugs and drug potentiators". Mr Radzieta's research arises from the collaboration between BioDiem and Western Sydney University's Antibiotic Resistance and Mobile Elements Group (ARMEG) led by Associate Professor Slade Jensen and located at the Ingham Institute for Applied Medical Research. This research focuses on BDM-I's activity against hospital pathogens such as MRSA (methicillin-resistant *Staphylococcus aureus* or "Golden Staph"). Results to date indicate that BDM-I's cellular target is novel and therefore BDM-I represents a next-generation anti-infective.

The WSU investigations are at the cutting edge of bacterial proteomics and genomics research into mechanisms of antibiotic resistance. Due to the lack of available options for the treatment of infections caused by MRSA (and other bacterial pathogens), development of new antimicrobial drugs such as BDM-I are urgently needed in order to combat the ever-growing threat that antimicrobial resistance represents. It is therefore important to elucidate the mechanism of action of this next-generation anti-infective, to facilitate its development.

BDM-I is being developed through BioDiem's subsidiary, Opal Biosciences Ltd. Opal Biosciences is currently seeking investors for the testing of BDM-I in nonclinical studies of infection. Success in infectious disease models will underpin the potential of BDM-I for prospective human use, and lead to clinical trials.

About WSU/AMREG

The ARMEG was founded by the Microbiology and Infectious Diseases Unit, WSU School of Medicine and its laboratory is located within the Ingham Institute for Applied Medical Research, which is a new purpose-built institute that serves as the centre of medical research in South West Sydney. The group's core research projects are centred on the evolution of antibiotic resistance in ESKAPE pathogens, particularly MRSA and VRE, but also has projects that examine the role of biofilms in hospital-acquired infections.

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with

other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on product sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the lack of new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit www.opalbiosciences.com.

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com